Moleculin's AML Trial Shows a Threefold Interim Remission Ad
Moleculin Biotech (Nasdaq: MBRX) reported preliminary unblinded interim efficacy from its MIRACLE pivotal AML trial on Aug. 14. In 45 patients, complete remission rates were 43% and 36% for Annamycin 190 and 230 mg/m² plus cytarabine versus 12% in control; composite CRc was 50% and 57% versus 29%. Company reported no cardiotoxicity to date and said cash was about $7.3M at June 30, 2026.
How this was made
The 30-second read
Why it matters
The article provides new interim unblinded efficacy numbers and a safety observation (no cardiotoxicity yet), but stresses that definitive analysis is for the full Part A population and Part B is not yet underway.
Market read
Traders may adjust probabilities for a positive pivotal outcome, but should price in interim-sample uncertainty and potential dilution ahead of the full readout window.
What to watch
Financing needs are highlighted with no commitments in place; dilution risk could cap upside even if interim efficacy looks strong.
Background
Moleculin Biotech is running the pivotal MIRACLE trial in relapsed or refractory AML with Annamycin plus cytarabine versus a control arm.
Ticker impact
Moleculin reported preliminary unblinded MIRACLE trial efficacy, with complete remission rates of 43% and 36% vs 12% control in first 45 patients.
Likely near-term bid on trial-readout optimism, with volatility as investors wait for full 90-patient Part A and later Part B.
The article discloses fresh interim unblinded efficacy and a safety detail, but emphasizes small sample size, incomplete enrollment, and no financing commitments despite a runway into Q1 2027.
Market effects
Reinforces investor appetite for anthracycline-like AML candidates that may reduce cardiotoxicity risk, but evidence remains interim.
Primarily US micro-cap biotech sentiment; limited direct regional spillover.
AML treatment efficacy and cardiotoxicity profiles are globally relevant, though impact is company-specific until larger datasets.
Counterpoint
The threefold interim remission advantage may not persist once the full 90-patient Part A dataset is analyzed, and the cardiotoxicity claim could weaken with more patients.
Key entities
- companyMoleculin Biotech
Nasdaq-listed sponsor of the MIRACLE pivotal trial reporting interim unblinded efficacy and cardiotoxicity observations.
- clinical_trialMIRACLE trial
Pivotal study in relapsed or refractory AML with Part A (definitive analysis) and Part B (dose selection).
- drugAnnamycin
Experimental anthracycline-class therapy combined with cytarabine; interim remission and cardiotoxicity signals are reported.
